- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04455503
Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1
A Phase 1/2, Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 After Complete Resection of Stage IIIB/IIIC/IIID or Stage IV Melanoma in Patients at High Risk for Recurrence
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will be conducted in two parts: a safety, efficacy and PD response part using two different drug delivery methods and an expansion cohort.
All patients will be administered with anti-PD-1 once every 4 weeks for up to 1 year commencing on Day 1 and with EVX-02 vaccine as soon as it is produced.
Part 1 will consist of two cohorts:
Cohort A: Will receive EVX- 02A delivered by delivery methodology 1. Cohort B: Will receive EVX- 02B delivered by delivery device 2. Part 2 (Cohort C) will be an expansion cohort. In this part, only one delivery methods, either EVX-02A or EVX-02B with will be used.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
New South Wales
-
Goulburn, New South Wales, Australia, 2170
- Liverpool Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5042
- Flinders Medical Centre
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Monash Medical Centre
-
Drummond, Victoria, Australia, 3350
- Ballarat Health Services
-
Melbourne, Victoria, Australia, 3000
- Peter MacCallum Cancer Centre
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Linear Cancer Trials
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed and dated written ICF prior to performing any protocol-related procedures, which are not part of normal standard care.
- Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, tumour sample including core needle biopsy as required, and other requirements of the study.
- Male or female ≥ 18 years of age at the time of informed consent.
Stage IIIB/IIIC/IIID or Stage IV AJCC (8th edition) (AJCC, 2018) before complete resection.
Please note: If Stage III melanoma (whether Stage IIIB or IIIC or IIID) the patients must have clinically detectable lymph nodes that are confirmed as malignant on the pathology report and/or ulcerated primary lesions, and/or in transit metastasis. The pathology report must be reviewed, signed and dated by the Investigator; this process must be done prior to enrolling patients into the study. Clinically detectable lymph nodes are defined as:
- a palpable node (confirmed as malignant by pathology) after the CLND
- a non-palpable but enlarged lymph node by CT scan (at least 15 mm in short axis) and confirmed as malignant by pathology after the CLND
- a PET scan positive lymph node of any size confirmed by pathology after CLND
- evidence of pathologically macro metastatic disease in one or more lymph nodes defined by one or more foci of melanoma at least 1 cm in diameter If Stage IV melanoma, the pathology report confirming negative margins must be reviewed, dated, and signed by the Investigator prior to randomisation.
- Cutaneous Melanoma, with metastases to regional lymph nodes or distant metastases, or in transit metastases, that can be surgically resected with negative margin on resected specimens.
- Specimen from the resected tumour tissue must be provided for evaluation by NGS.
- ECOG performance status score of 0 or 1.
Screening laboratory values must meet the following criteria and must be reconfirmed for eligibility within 72 hours prior to first dose of anti-PD-1 on Day 1:
i. WBCs ≥ 2000/μL (2.0 x 109/L) ii. Neutrophils ≥ 1500/μL (1.5 x109/L) iii. Platelets ≥ 100 x 10³/μL (100 x 109/L) iv. Haemoglobin ≥ 9.0 g/dL (90 g/L) v. Creatinine Serum creatinine ≤ 1.5 x ULN or creatinine clearance > 40 mL/minute (using Cockcroft/Gault formula) vi. AST ≤ 3 x ULN vii. ALT ≤ 3 x ULN viii. Total Bilirubin ≥ 1.5 x ULN (except patients with Gilbert Syndrome who must have total bilirubin < 3.0 mg/dL)
- Life expectancy > 6 months at Screening.
- WOCBP and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of hCG]) within 24 hours prior to first dose of anti-PD-1 on Day 1.
- WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug (s) plus 5 half-lives of study drug plus 30 days (duration of ovulatory cycle). The half-life of nivolumab is up to 25 days. WOCBP should therefore use an adequate method to avoid pregnancy for a total of 23 weeks post-treatment completion.
- Men who are sexually active with a WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of the study drug(s) plus 90 days (duration of sperm turnover). The half-life of nivolumab is up to 25 days, men should therefore use an adequate method of contraception for a total of 31 weeks post-treatment completion.
- Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements. However, WOCBP must still undergo pregnancy testing.
- Disease-free at study enrolment (after surgery) based upon pathology report review by the Investigator.
Exclusion Criteria:
Known or active other malignancies that have needed treatment (excluding palliative radiation) within 2 years prior to Cycle 1 Day 1 are excluded except for the following:
- Curatively resected non-melanomatous skin cancer
- Curatively treated cervical carcinoma in situ
- Non-metastatic breast and prostate cancer patients with stable disease > 12 months
- Other stable malignancies may be permitted based on case-by-case discussions with Sponsor and Medical Monitor approval.
- Patients with clinically occult lymph nodes (i.e. detected by SLN biopsy) stage N1a and N2a.
- Participated in any other investigational study, unless treatment in that study has been discontinued at least 30 days or period of five half-lives prior to Screening.
- Known or suspected allergy or hypersensitivity to any of the therapeutic agents to be administered during the study.
- Uncontrolled concurrent illness including, but not limited to, active infection, symptomatic congestive heart failure or cardiac arrhythmia.
- Has a history of clinically significant GI disease, renal, hepatic, neurologic, haematologic, endocrine, oncologic, pulmonary, immunologic, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardise the safety of the patient or impact the validity of the study results.
- Uncontrolled mental disease or psychotic manifestation that, in the opinion of the Investigator, would prohibit compliance with the protocol, the understanding of the ICF, or the ability to withdraw from the study.
- Known history of or positive test for HIV or known immunodeficiency syndrome (AIDS).
- For patients with evidence of chronic HBV infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
- Patients with a history of HCV infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
- Pregnant or nursing women.
- Ocular or uveal melanoma.
- History of carcinomatosis meningitis.
- History of Grade ≥ 3 allergy to human monoclonal antibodies.
- Active, known, or suspected autoimmune disease or immunosuppressive conditions with the exception of vitiligo, type 1 diabetes, residual autoimmune-related hypothyroidism requiring hormone replacement, or psoriasis not requiring systemic treatment.
- Prior treatment with immune-modulatory agents including, but not limited to: IL-2, CTLA-4 blockade, PD-1/PD-L1 blockade, CD40 stimulation, CD137 stimulation - with the exception of IFN-α given as adjuvant treatment for high risk, surgically resected melanoma (Note. IFN-α therapy must have been discontinued more than 4 weeks prior to enrolment in the study).
- Prior investigational melanoma-directed cancer vaccine therapy.
- Prior chemotherapy, including targeted therapy such as BRAF or MEK inhibition.
- Use of a non-oncology vaccine therapy for prevention of infectious diseases up to 4 weeks prior to enrolment in the study.
- Patients with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to first dose of anti-PD-1 on Day 1. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A: Nivolumab and EVX-02A
EVX-02A administered IM.
|
Up to 8 patients will receive EVX-02A administered IM.
Other Names:
|
Experimental: Cohort B: Nivolumab and EVX-02B
EVX-02B administered IM.
|
Up to 8 patients will receive EVX-02B administered IM.
Other Names:
|
Experimental: Cohort C: Nivolumab and EVX-02A OR Nivolumab and EVX-02B
The selected delivery methodology either EVX02A or EVX-02B.
|
EVX-02A or EVX-02B will be used.
Patients: 24 to 30
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability (Incidence of Treatment-Emergent Adverse Events)
Time Frame: Measurements at Baseline through study completion, an average of 1 year
|
Measure through CTCAE version 5.0
|
Measurements at Baseline through study completion, an average of 1 year
|
Safety and tolerability (Incidence of Treatment-Emergent Adverse Events) measure through Vital Sign- blood pressure
Time Frame: Measurements at Baseline through study completion, an average of 1 year
|
Measured by result of the Vital Sign- blood pressure
|
Measurements at Baseline through study completion, an average of 1 year
|
Safety and tolerability (Incidence of Treatment-Emergent Adverse Events) measure through Vital Sign-heart rate
Time Frame: Measurements at Baseline through study completion, an average of 1 year
|
Measured by result of the Vital Sign- heart rate
|
Measurements at Baseline through study completion, an average of 1 year
|
Safety and tolerability (Incidence of Treatment-Emergent Adverse Events) measure through Physical exam
Time Frame: Measurements at Baseline through study completion, an average of 1 year
|
Measured by result of the physical exam which includes general appearance, skin, eyes/ears/nose/throat, head and neck.
|
Measurements at Baseline through study completion, an average of 1 year
|
Pharmacodynamic response (PD) of EVX-02 assessed by IFN-y ELISPOT
Time Frame: Measurements at Baseline through study completion, an average of 1 year
|
The pharmacodynamic (PD) response of EVX-02 will be assessed by detecting vaccine induced circulating neoepitope-specific T cells.
Blood samples will be collected prior, during and after immunization and the immunotherapy induced T cell responses will be assayed by IFN-y ELISPOT.
|
Measurements at Baseline through study completion, an average of 1 year
|
Pharmacodynamic response (PD) of EVX-02 assessed by MHC I multimer analysis
Time Frame: Measurements at Baseline through study completion, an average of 1 year
|
The pharmacodynamic (PD) response of EVX-02 will be assessed by detecting vaccine induced circulating neoepitope-specific T cells.
Blood samples will be collected prior, during and after immunization.
The samples will be analyzed by MHC I multimer analyses detecting neoepitope-recognizing CD8+ T cells reported as frequencies of positive cell out of CD8+ T cells.
|
Measurements at Baseline through study completion, an average of 1 year
|
Pharmacodynamic response (PD) of EVX-02 by intracellular cytokine staining and flow cytometry
Time Frame: Measurements at Baseline through study completion, an average of 1 year
|
The pharmacodynamic (PD) response of EVX-02 will be assessed by detecting vaccine induced circulating neoepitpe-specific T cells.
Blood samples will be collected prior, during and after immunization.
The samples will be analysed by flow cytometry to detect vaccine induced intracellular cytokine response, reported as frequencies of neoepitope-reactive CD4+ cells and CD8+ T cells.
|
Measurements at Baseline through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy measure through Relapse-free survival (RFS)
Time Frame: Measurements at Baseline through study completion, an average of 1 year
|
Measured by result of Relapse-free survival (RFS)
|
Measurements at Baseline through study completion, an average of 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PD response of EVX-02 assessed by monitoring the quantity of cfDNA in plasma
Time Frame: Measured at Screening, Day -84 to Day -1, Day 1, Day 84, Day 168, Day 252, Day 336 and early termination
|
To monitor the plasma level cfDNA, blood sample will be obtained prior, during and after treatment with EVX-02 and the fluctuations of the level cfDNA will be analysed.
|
Measured at Screening, Day -84 to Day -1, Day 1, Day 84, Day 168, Day 252, Day 336 and early termination
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dr Bavanthi Balakrishnar, Liverpool Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EVX-02-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma Stage IV
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage IV Cutaneous Melanoma AJCC v6 and v7 | Ocular Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Cutaneous Melanoma | Mucosal Melanoma | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Stage IIIB Uveal Melanoma AJCC v7 | Stage IIIC Uveal Melanoma AJCC v7 | Stage III Acral... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedMetastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma AJCC v7United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Incyte Corporation; University of VirginiaCompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma | Stage IIIA Skin Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma | Recurrent Uveal MelanomaUnited States
-
Elizabeth Buchbinder, MDGenentech, Inc.RecruitingStage IV Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Unresectable Stage III Cutaneous Melanoma | Unresectable Stage IV Cutaneous MelanomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma... and other conditionsUnited States
-
Yale UniversityNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC MelanomaUnited States
Clinical Trials on EVX-02A
-
Evaxion Biotech A/SMerck Sharp & Dohme LLCRecruitingMelanoma Stage IV | Melanoma Stage IIIAustralia